aluates Reports

$ 0.0

Automative

Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Research Report 2024

Published Date: March 2024

Report Code: QYRE-Auto-31V7578

Global VPM1002 Tuberculosis BCG Based Vaccine for Prevent Covid 19 Market Insights Forecast to 2028

BUY CHAPTERS

Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Research Report 2024

Code: QYRE-Auto-31V7578

Report

March 2024

Pages:67

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Vakzine Projekt Management (VPM)

VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market

As for March 26, 2020

1.BCG Vaccine Clinical Experiment for Against Covid-19

Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.

Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.

The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.

2.Introduce of VPM1002，a Genetically Modified More Effective BCG Vaccine

VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.

The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.

Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.

3.Research Progress for VPM1002

Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.

The vaccine is currently being tested in a further Phase III study on adult volunteers in India.

The global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.

Report Scope

The VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Report

Report Metric	Details
Report Name	VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market
CAGR	5%
Segment by Type	by Dosage 0.5ml Package 1ml Package 2ml Package Other
by Type of Inoculator	Initial Vaccinate Revaccination
Segment by Application	0-5 Years Old 5-18 Years Old 18-45 Years Old 45-65 Years Old ≥65 Years Old
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Vakzine Projekt Management (VPM), Serum Institute of India
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market report?

Ans: The main players in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market are Vakzine Projekt Management (VPM), Serum Institute of India

What are the Application segmentation covered in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market report?

Ans: The Applications covered in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market report are 0-5 Years Old, 5-18 Years Old, 18-45 Years Old, 45-65 Years Old, ≥65 Years Old

What are the Type segmentation covered in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market report?

Ans: The Types covered in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market report are Initial Vaccinate, Revaccination

1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Overview

1.1 Product Overview and Scope of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19

1.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Dosage

1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Value Comparison by Dosage (2024-2030)

1.2.2 0.5ml Package

1.2.3 1ml Package

1.2.4 2ml Package

1.2.5 Other

1.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Application

1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Value by Application: (2024-2030)

1.3.2 0-5 Years Old

1.3.3 5-18 Years Old

1.3.4 18-45 Years Old

1.3.5 45-65 Years Old

1.3.6 ≥65 Years Old

1.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Estimates and Forecasts

1.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2030

1.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2030

1.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Competition by Manufacturers

2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Manufacturers (2019-2024)

2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Manufacturers (2019-2024)

2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Average Price by Manufacturers (2019-2024)

2.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, Product Type & Application

2.7 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Competitive Situation and Trends

2.7.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Players Market Share by Revenue

2.7.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Retrospective Market Scenario by Region

3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region: 2019-2030

3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region: 2019-2024

3.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region: 2025-2030

3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region: 2019-2030

3.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region: 2019-2024

3.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region: 2025-2030

3.4 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country

3.4.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2030)

3.4.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country

3.5.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2030)

3.5.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country

3.6.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2030)

3.6.3 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country

3.7.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2030)

3.7.3 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country

3.8.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2030)

3.8.3 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2030)

4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024)

4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2025-2030)

4.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2030)

4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2019-2030)

4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2019-2024)

4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2025-2030)

4.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2019-2030)

4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2019-2030)

5 Segment by Application

5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2030)

5.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024)

5.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2025-2030)

5.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2030)

5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2019-2030)

5.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2019-2024)

5.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2025-2030)

5.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2019-2030)

5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Vakzine Projekt Management (VPM)

6.1.1 Vakzine Projekt Management (VPM) Corporation Information

6.1.2 Vakzine Projekt Management (VPM) Description and Business Overview

6.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolio

6.1.5 Vakzine Projekt Management (VPM) Recent Developments/Updates

6.2 Serum Institute of India

6.2.1 Serum Institute of India Corporation Information

6.2.2 Serum Institute of India Description and Business Overview

6.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolio

6.2.5 Serum Institute of India Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industry Chain Analysis

7.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Mode & Process

7.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales and Marketing

7.4.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Channels

7.4.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors

7.5 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customers

8 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Dynamics

8.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industry Trends

8.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers

8.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Challenges

8.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Vakzine Projekt Management (VPM)

List of Tables

Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Competitive Situation by Manufacturers in 2023

Table 4. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) of Key Manufacturers (2019-2024)

Table 5. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Manufacturers (2019-2024)

Table 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Average Price (USD/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, Product Type & Application

Table 12. Global Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019-2024) & (K Doses)

Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2019-2024)

Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2025-2030) & (K Doses)

Table 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2025-2030)

Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2019-2024)

Table 23. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2025-2030)

Table 25. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)

Table 27. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2025-2030) & (K Doses)

Table 28. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)

Table 32. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2025-2030) & (K Doses)

Table 33. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019-2024) & (K Doses)

Table 37. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2025-2030) & (K Doses)

Table 38. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)

Table 42. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2025-2030) & (K Doses)

Table 43. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)

Table 47. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2025-2030) & (K Doses)

Table 48. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) by Type (2019-2024)

Table 51. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) by Type (2025-2030)

Table 52. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)

Table 53. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2025-2030)

Table 54. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (US$ Million) by Type (2019-2024)

Table 55. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (US$ Million) by Type (2025-2030)

Table 56. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2019-2024)

Table 57. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2025-2030)

Table 58. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (USD/Dose) by Type (2019-2024)

Table 59. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (USD/Dose) by Type (2025-2030)

Table 60. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) by Application (2019-2024)

Table 61. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) by Application (2025-2030)

Table 62. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)

Table 63. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2025-2030)

Table 64. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (US$ Million) by Application (2019-2024)

Table 65. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (US$ Million) by Application (2025-2030)

Table 66. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2019-2024)

Table 67. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2025-2030)

Table 68. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (USD/Dose) by Application (2019-2024)

Table 69. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (USD/Dose) by Application (2025-2030)

Table 70. Vakzine Projekt Management (VPM) Corporation Information

Table 71. Vakzine Projekt Management (VPM) Description and Business Overview

Table 72. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 73. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product

Table 74. Vakzine Projekt Management (VPM) Recent Developments/Updates

Table 75. Serum Institute of India Corporation Information

Table 76. Serum Institute of India Description and Business Overview

Table 77. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 78. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product

Table 79. Serum Institute of India Recent Developments/Updates

Table 80. Key Raw Materials Lists

Table 81. Raw Materials Key Suppliers Lists

Table 82. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors List

Table 83. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customers List

Table 84. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Trends

Table 85. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers

Table 86. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Challenges

Table 87. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints

Table 88. Research Programs/Design for This Report

Table 89. Key Data Information from Secondary Sources

Table 90. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19

Figure 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Type in 2023 & 2030

Figure 4. 0.5ml Package Product Picture

Figure 5. 1ml Package Product Picture

Figure 6. 2ml Package Product Picture

Figure 7. Other Product Picture

Figure 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Application in 2023 & 2030

Figure 10. 0-5 Years Old

Figure 11. 5-18 Years Old

Figure 12. 18-45 Years Old

Figure 13. 45-65 Years Old

Figure 14. ≥65 Years Old

Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size (2019-2030) & (US$ Million)

Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (2019-2030) & (K Doses)

Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Average Price (USD/Dose) & (2019-2030)

Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Report Years Considered

Figure 20. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Manufacturers in 2023

Figure 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Manufacturers in 2023

Figure 22. The Global 5 and 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Players: Market Share by Revenue in 2023

Figure 23. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 25. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2030)

Figure 26. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2030)

Figure 27. U.S. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Canada VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2030)

Figure 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2030)

Figure 31. Germany VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. France VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. U.K. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Italy VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Russia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2019-2030)

Figure 37. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2019-2030)

Figure 38. China VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Japan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Australia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Indonesia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Thailand VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Malaysia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Philippines VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2030)

Figure 49. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2030)

Figure 50. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2030)

Figure 54. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2030)

Figure 55. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 57. UAE VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. Global Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Type (2019-2030)

Figure 59. Global Revenue Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Type (2019-2030)

Figure 60. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (USD/Dose) by Type (2019-2030)

Figure 61. Global Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Application (2019-2030)

Figure 62. Global Revenue Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Application (2019-2030)

Figure 63. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (USD/Dose) by Application (2019-2030)

Figure 64. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Value Chain

Figure 65. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Process

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Distributors Profiles

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions